National Diabetes Audit - 2011-12: Report 2
Publication date: 00:05 November 28, 2013
2011-2012 National Diabetes Audit (NDA) report.
Report 2 shows Complications and Mortality
This national report from the ninth year of the NDA, presents key findings on complications in 2010-2012 and deaths in 2012 for all age groups. This report presents statistics about diabetes outcomes including Diabetic Ketoacidosis (DKA), chronic kidney disease and treatment of end stage disease (renal replacement therapy, RRT), lower limb amputations, retinopathy treatment, heart disease, stroke and mortality.
Due to the size of this publication, the data have been organised alphabetically by CCG/LHB profile and split into several pages, which are linked to above.
- More than a quarter of admissions to hospital with heart failure involve a patient with diabetes (28 per cent, or 198,200 of 717,100 admissions during 2010-2012).
- The National Diabetes Audit published today recorded over two million patients with diabetes and shows people with diabetes have a 74 per cent greater risk of being admitted to hospital for heart failure compared to the rest of the population.
- Of the 198,100 people in the audit with type 1 diabetes in England and Wales in 2012, 3,300 died during the year, whereas 1,440 would have been expected among the same number of the general population, giving a 130 per cent increased risk of death for people with this form of diabetes.
- Of the 1.9million people in the audit with type 2 diabetes in England and Wales in 2012, 70,900 died during the year, whereas 52,800 would have been expected among the same number of the general population, giving a 35 per cent increased risk of death for people with this form of diabetes.
- The risk of premature death for people with diabetes. compared to their peers in the general population (relative risk) is greatest for women and younger people.
|Date Range:||01 January 2011 to 31 March 2012|
|Geographical coverage:||England and Wales|
|Geographical granularity:||NHS Trusts, Primary Care Organisations, Clinical Commissioning Groups|